Amorphical conducted a series of studies in the field of oncology. At first, ACC was found effective in a study conducted on mammary gland cancer cells that were injected into the bone for induction of bone metastasis. The study demonstrated that ACC treatment raised the survival rate and increased mice vitality.
Next, Amorphical examined the cellular metabolism profile of the mammary gland cancer cells which were treated with ACC. The study was performed by a novel technology, Seahorse, which allows measurement of cells respiration. The results revealed that cancer cells grown in a medium enriched with ACC demonstrated less glycolytic respiration and preferred aerobic respiration, compared to control treatments.
An additional study found a significant reduction in the growth rate of a Lewis Lung Carcinoma (LLC) tumor. In this study LLC cells were injected subcutaneous into mice, developed into tumours. Mice were then treated with ACC and additional controls for several days and tumor size was measured.
Moreover, preliminary result demonstrated that ACC affects the immune system. By studying the spleen phenotype profile, it was found that ACC can mediate a shift towards immune activation and Th1 polarization; i.e. the spleen cells of mice that were administered with ACC had a higher expression of leukocytes and a greater ratio of CD8/CD4 cells.
In the next studies, Amorphical aims to explore the specific mechanism in which ACC affects tumor and cancer cells. Specifically, to investigate its activity on tumor microenvironment and on the immune system and its recruitment against cancer.
In September 2017, the company has started an Open label clinical study for improving the functionality and quality of life for patients with advanced solid cancer (with or without metastases in lung), by treating with Amorphous Calcium Carbonate (ACC), orally administrated combined with inhalation.
A series of studies explored the effect of ACC on a mice model for Muscular Dystrophy Disease, Duchenne. In one study, mice model for Duchenne (MDX) which were treated orally with ACC revealed significantly lower Creatine Kinase levels i.e., less muscle dissociation compared to mice that were orally administered with crystalline calcium carbonate.
In a second study, ACC was orally administrated for a period of six months. This study showed a clear trend of improvement in mice muscle functionality. Based on these results, Amorphical is now focusing on investigation the effect of ACC on muscle fatigue both in-vivo and in cells cultures.